Hepatitis B vaccine

Hepatitis B vaccine
Hepatitis B vaccine
Vaccine description
Target disease Hepatitis B
Type Subunit
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a607014
Pregnancy cat.  ?
Legal status  ?
Identifiers
ATC code J07BC01
 N(what is this?)  B vaccine (verify)

Hepatitis B vaccine is a vaccine developed for the prevention of hepatitis B virus infection. The vaccine contains one of the viral envelope proteins, hepatitis B surface antigen (HBsAg). It is produced by yeast cells, into which the genetic code for HBsAg has been inserted.[1] A course of three (3) vaccine injections are given with the second injection at least one month after the first dose and the third injection given six months after the first dose.[2] Afterward an immune system antibody to HBsAg is established in the bloodstream. The antibody is known as anti-HBsAg. This antibody and immune system memory then provide immunity to hepatitis B infection.[3] The first vaccine became available in 1981.

A range of vaccines are available in the market. Presently recombinant DNA vaccines are available, which means they are produced by inserting the gene for HBV into common baker's yeast where it is grown, harvested, and purified. HBV infection cannot occur from receiving hepatitis B vaccine. The common brands available are Engerix-B (GSK), Elovac B (Human Biologicals Institute, A division of Indian Immunologicals Limited), Genevac B (Serum Institute), Shanvac B etc. These vaccines are given intramuscularly.

Contents

The invention

The invention of the vaccine began with the realization (by virologist Alfred Prince, in 1968) that the Australia antigen was part of a virus that caused hepatitis. Maurice Hilleman at Merck used three treatments (pepsin, urea and formaldehyde) of blood serum together with rigorous filtration to yield a product that could be used as a safe vaccine. This was first licensed by the FDA in 1981. It was not very successful in the marketplace because clinicians knew that it was a product made from human blood serum. It was withdrawn from the marketplace when Pablo DT Valenzuela, Research Director of Chiron Corporation succeeded in 1986 in making the antigen in yeast and invented the first recombinant vaccine [4]. This is the vaccine still in use today.

Recommended populations

Babies born to mothers ware vaccinated with hepatitis B surface antigen (HBsAg) and injected with hepatitis B immunoglobulin (HBIG).[5]

Many countries now routinely vaccinate infants against hepatitis B. In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer. This was reported in Taiwan where the implementation of a nationwide hepatitis B vaccination program in 1984 was associated with a decline in the incidence of childhood hepatocellular carcinoma.[6]

In many areas, vaccination against hepatitis B is also required for all health-care and laboratory staff.[7]

An Australian couple in August 2008 went on the run after the New South Wales Supreme Court extended an order forcing them to immunise their newborn against the disease. DOCS (Department of Community Services) took out the order, as doctors say the five-day-old baby is at a high risk of contracting the illness as his mother has the disease. The parents believe (see Vaccine controversy) that aluminium in the vaccine would cause the baby more harm than the disease itself.[8][9]

Response to vaccination

Following the primary course of 3 vaccinations, a blood test may be taken after an interval of 1–4 months to establish if there has been an adequate response, which is defined as an anti-hepatitis B surface antigen (anti-Hbs) antibody level above 100 mIU/ml. Such a full response occurs in about 85-90% of individuals.[10]

An antibody level between 10 and 100 mIU/ml is considered a poor response, and these people should receive a single booster vaccination at this time, but do not need further retesting.[10]

People who fail to respond (anti-Hbs antibody level below 10 mIU/ml) should be tested to exclude current or past Hepatitis B infection, and given a repeat course of 3 vaccinations, followed by further retesting 1–4 months after the second course. Those who still do not respond to a second course of vaccination may respond to intradermal administration[11] or to a high dose vaccine [12] or to a double dose of a combined Hepatitis A and B vaccine.[13] Those who still fail to respond will require hepatitis B immunoglobulin (HBIG) if later exposed to the hepatitis B virus.[10]

Poor responses are mostly associated with being over the age of 40 years, obesity and smoking,[14] and also in alcoholics, especially if with advanced liver disease.[15] Patients who are immunosuppressed or on renal dialysis may respond less well and require larger or more frequent doses of vaccine.[10] At least one study suggests that hepatitis B vaccination is less effective in patients with HIV.[16]

Duration of protection

It is now believed that the hepatitis B vaccine provides indefinite protection. However, it was previously believed and suggested that the vaccination would only provide effective cover of between five and seven years,[17][18] but subsequently it has been appreciated that long-term immunity derives from immunological memory which outlasts the loss of antibody levels and hence subsequent testing and administration of booster doses is not required in successfully vaccinated immunocompetent individuals.[19][20] Hence with the passage of time and longer experience, protection has been shown for at least 25 years in those who showed an adequate initial response to the primary course of vaccinations,[21] and UK guidelines now suggest that for initial responders who require ongoing protection, such as for healthcare workers, only a single booster is advocated at 5 years.[10]

Safety

Several studies looked for a significant association between recombinant hepatitis B vaccine (HBV) and multiple sclerosis (MS) in adults. Most published scientific studies do not support a causal relationship between hepatitis B vaccination and demyelinating diseases such as MS.[22] A 2004 study[23] reported a significant increase in risk within 3 years of vaccination. Some of these studies were criticized for methodological problems. This controversy created public misgivings about HB vaccination, and hepatitis B vaccination in children remained low in several countries. A 2007 study found that the vaccination does not seem to increase the risk of a first episode of MS in childhood.[24]

A 2009 study of the hepatitis B vaccine and associated risk of CNS inflammatory demyelination was conducted. The hepatitis B vaccine was found to be generally safe, however the Engerix B vaccine appeared to triple the risk of CNS inflammatory demyelination in infant boys.[25] There have been numerous reports that the Hepatitis B vaccine is linked to Chronic Fatigue Syndrome, a syndrome marked by severe fatigue, brain fogs, and muscle pains among other symptoms. [26] The Engerix B vaccine contained Thiomersal, a mercury containing vaccine preservative that is being phased out at the urging of the Public Health Service in the US.[27]

References

  1. ^ "Hepatitis B Vaccine from Merck". http://www.rxlist.com/recombivax-drug.htm. Retrieved 2010-05-09. 
  2. ^ "Hepatitis B Vaccine". Doylestown, Pennsylvania: Hepatitis B Foundation. 2009-01-31. http://www.hepb.org/hepb/vaccine_information.htm. Retrieved 2009-10-22. 
  3. ^ "CDC Viral Hepatitis". Atlanta, Georgia: Centers for Disease Control and Prevention. 2009-07-24. http://www.cdc.gov/hepatitis/index.htm. Retrieved 2009-10-22. 
  4. ^ [1] The New York Times
  5. ^ Mast; Margolis, H. S.; Fiore, A. E.; Brink, E. W.; Goldstein, S. T.; Wang, S. A.; Moyer, L. A.; Bell, B. P. et al. (2005). "A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents" (Free full text). MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control 54 (RR–16): 1–31. PMID 16371945. http://www.cdc.gov/mmwr/PDF/rr/rr5416.pdf.  edit
  6. ^ Chang, M. -H.; Chen, C. -J.; Lai, M. -S.; Hsu, H. -M.; Wu, T. -C.; Kong, M. -S.; Liang, D. -C.; Shau, W. -Y. et al. (1997). "Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children". New England Journal of Medicine 336 (26): 1855–1859. doi:10.1056/NEJM199706263362602. PMID 9197213.  edit
  7. ^ Joint Committee on Vaccination and Immunisation (2006). "Chapter 12 Immunisation of healthcare and laboratory staff -- Hepatitis B" (PDF). Immunisation Against Infectious Disease 2006 ("The Green Book") (3rd ed.). Edinburgh: Stationery Office. pp. 468. ISBN 0113225288. http://www.dh.gov.uk/en/Publichealth/Healthprotection/Immunisation/Greenbook/DH_4097254?IdcService=GET_FILE&dID=115800&Rendition=Web. 
  8. ^ "Evidence supports action against 'hep B' baby's parents: DOCS". Sydney, Australia: ABC News. 2008-08-25. http://www.abc.net.au/news/stories/2008/08/25/2346031.htm. Retrieved 2009-10-22. 
  9. ^ "Court extends order for 'hep B' baby". Croydon Park, Australia: ABC News. 2008-08-25. http://www.abc.net.au/news/stories/2008/08/25/2345782.htm. Retrieved 2009-10-22. 
  10. ^ a b c d e Joint Committee on Vaccination and Immunisation (2006). "Chapter 18 Hepatitis B" (PDF). Immunisation Against Infectious Disease 2006 ("The Green Book") (3rd edition (Chapter 18 revised 10 October 2007) ed.). Edinburgh: Stationery Office. pp. 468. ISBN 0113225288. http://www.dh.gov.uk/en/Publichealth/Healthprotection/Immunisation/Greenbook/DH_4097254?IdcService=GET_FILE&dID=152019&Rendition=Web. 
  11. ^ King; Taylor, E. M.; Crow, S. D.; White, M. C.; Todd, J. R.; Poe, M. B.; Conrad, S. A.; Gelder, F. B. (1990). "Comparison of the immunogenicity of hepatitis B vaccine administered intradermally and intramuscularly". Reviews of infectious diseases 12 (6): 1035–1043. doi:10.1093/clinids/12.6.1035. PMID 2148433.  edit
  12. ^ Levitz; Cooper, B.; Regan, H. (1995). "Immunization with high-dose intradermal recombinant hepatitis B vaccine in healthcare workers who failed to respond to intramuscular vaccination". Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 16 (2): 88–91. doi:10.1086/647062. PMID 7759824.  edit
  13. ^ Cardell, K.; Åkerlind, B.; Sällberg, M.; Frydén, A. (2008). "Excellent Response Rate to a Double Dose of the Combined Hepatitis a and B Vaccine in Previous Nonresponders to Hepatitis B Vaccine". The Journal of Infectious Diseases 198 (3): 299–226. doi:10.1086/589722. PMID 18544037.  edit
  14. ^ Roome, A. J.; Walsh, S.; Cartter, M.; Hadler, J. (1993). "Hepatitis B vaccine responsiveness in Connecticut public safety personnel". Journal of the American Medical Association 270 (24): 2931–2934. doi:10.1001/jama.270.24.2931. PMID 8254852.  edit
  15. ^ Rosman, Md, A.; Basu, P.; Galvin, K.; Lieber, C. (1997). "Efficacy of a High and Accelerated Dose of Hepatitis B Vaccine in Alcoholic Patients a Randomized Clinical Trial". The American Journal of Medicine 103 (3): 217–222. doi:10.1016/S0002-9343(97)00132-0. PMID 9316554.  edit
  16. ^ Pasricha, N.; Datta, U.; Chawla, Y.; Singh, S.; Arora, S.; Sud, A.; Minz, R.; Saikia, B. et al. (2006). "Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine". BMC Infectious Diseases 6: 65. doi:10.1186/1471-2334-6-65. PMC 1525180. PMID 16571140. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1525180.  edit Cold or Flu like symptoms can develop after receiving the vaccine, but these are short lived. As with any injection, the muscle can become tender around the injection point for some time afterwards
  17. ^ Krugman; Davidson, M. (1987). "Hepatitis B vaccine: prospects for duration of immunity". The Yale journal of biology and medicine 60 (4): 333–339. PMC 2590237. PMID 3660859. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2590237.  edit
  18. ^ Petersen, K. M.; Bulkow, L. R.; McMahon, B. J.; Zanis, C.; Getty, M.; Peters, H.; Parkinson, A. J. (2004). "Duration of Hepatitis B Immunity in Low Risk Children Receiving Hepatitis B Vaccinations from Birth" (Free full text). The Pediatric Infectious Disease Journal 23 (7): 650–655. doi:10.1097/01.inf.0000130952.96259.fd. PMID 15247604. http://www.medscape.com/viewarticle/483473.  edit
  19. ^ Gabbuti, A.; Romanò, L.; Blanc, P.; Meacci, F.; Amendola, A.; Mele, A.; Mazzotta, F.; Zanetti, A. R. (2007). "Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents". Vaccine 25 (16): 3129–3132. doi:10.1016/j.vaccine.2007.01.045. PMID 17291637.  edit
  20. ^ "Are booster immunisations needed for lifelong hepatitis B immunity?". The Lancet 355 (9203): 561–565. 2000. doi:10.1016/S0140-6736(99)07239-6. PMID 10683019.  edit
  21. ^ Vandamme, P.; Van Herck, K. (2007). "A review of the long-term protection after hepatitis a and B vaccination". Travel Medicine and Infectious Disease 5 (2): 79–84. doi:10.1016/j.tmaid.2006.04.004. PMID 17298912.  edit
  22. ^ FAQs about Hepatitis B Vaccine (Hep B) and Multiple Sclerosis, CDC
  23. ^ Hernán; Jick, S. S.; Olek, M. J.; Jick, H. (2004). "Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study". Neurology 63 (5): 838–842. PMID 15365133.  edit
  24. ^ Mikaeloff, Y.; Caridade, G.; Rossier, M.; Suissa, S.; Tardieu, M. (2007). "Hepatitis B Vaccination and the Risk of Childhood-Onset Multiple Sclerosis". Archives of Pediatrics & Adolescent Medicine 161 (12): 1176–1182. doi:10.1001/archpedi.161.12.1176. PMID 18056563.  edit
  25. ^ "Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood". Neurology. 2009. http://www.neurology.org/cgi/content/abstract/72/10/873. 
  26. ^ Lanctot MD, Guylaine. "Association of American Physicians&Surgeons Report". Association of American Physicians&Surgeons Report. VRAN. http://vran.org/vaccines/hepatitis/cfs.htm. Retrieved 11 March 2011. 
  27. ^ "Thiomersal in Vaccines". U.S. Food and Drug Administration. 2010-03-31. http://www.fda.gov/biologicsbloodvaccines/safetyavailability/vaccinesafety/ucm096228.htm. 
v · d · eArtificial induction of immunity / Immunization: Vaccines, Vaccination, and Inoculation (J07)
Development

List of vaccine ingredients · Adjuvants · Mathematical modelling · Timeline · Trials

Classes: Inactivated vaccine · Live vector vaccine (Attenuated vaccine, Heterologous vaccine) · Toxoid · Subunit/component / Peptide / Virus-like particle · Conjugate vaccine · DNA vaccination
Administration
Global: GAVI Alliance · Policy · Schedule · Vaccine injury
USA: ACIP · VAERS · VSD · Vaccine court · Vaccines for Children Program
Vaccines
Bacterial

Anthrax · Brucellosis · Cholera# · Diphtheria# · Hib# · Meningococcus# (NmVac4-A/C/Y/W-135, NmVac4-A/C/Y/W-135 - DT, MeNZB) · Pertussis# · Plague · Pneumococcal# (PPSV, PCV) · Tetanus# · Tuberculosis (BCG)# · Typhoid# (Ty21a, ViCPS) · Typhus

combination: DTwP/DTaP
Viral

Adenovirus · Tick-borne encephalitis · Japanese encephalitis# · Flu# (LAIV, H1N1 (Pandemrix)) · Hepatitis A# · Hepatitis B# · HPV (Gardasil, Cervarix) · Measles# · Mumps# (Mumpsvax) · Polio# (Salk, Sabin) · Rabies# · Rotavirus# · Rubella# · Smallpox (Dryvax) · Varicella zoster (chicken pox#, shingles) · Herpes simplex† · Yellow fever#
combination: MMR · MMRV

research: Cytomegalovirus · Epstein-Barr · HIV · Hepatitis C
Protozoan
Malaria · Trypanosomiasis
Schistosomiasis · Hookworm
Other
TA-CD • TA-NIC · NicVAX · Cancer vaccines (ALVAC-CEA vaccine, Hepatitis B# · HPV (Gardasil, Cervarix))
Controversy
See also

M: BAC

bact (clas)

gr+f/gr+a(t)/gr-p(c)/gr-o

drug(J1p, w, n, m, vacc)

M: VIR

virs(prot)/clss

cutn/syst (hppv/hiva, infl/zost/zoon)/epon

drugJ(dnaa, rnaa, rtva, vacc)
v · d · e   Genetic engineering
Genetically
modified
organisms
Mammals
Mouse (Knockout mouse · Oncomouse) · Enviropig · Herman the Bull · Knockout rat
Maize
MON 809 · MON 810 · MON 863
Potato
Amflora
Rice
Soybean
Roundup Ready soybean · Vistive Gold
Tomato
Fish tomato · Flavr Savr
Cotton
Bt cotton · Roundup Ready cotton
Other
Tobacco · Arabidopsis · Canola · Brinjal · Rose
Fish
Glofish · Salmon
Bacteria and viruses
Ice-minus bacteria · Hepatitis B vaccine · Onyx-015
Processes
Types
Uses
In agriculture
In humans and diagnostics
Gene therapy · Genetic enhancement
In research
Related articles
Similar fields

External links


Wikimedia Foundation. 2010.

Игры ⚽ Нужно сделать НИР?

Look at other dictionaries:

  • Hepatitis A vaccine — Hepatitis A Vaccine, (brand names include Havrix or Avaxim), is a vaccine against the Hepatitis A virus. The vaccine protects against the virus in more than 95% of cases and provides protection from the virus for at least ten years. The vaccine… …   Wikipedia

  • hepatitis A vaccine — A vaccine used to prevent infection with the hepatitis A virus, which causes a serious liver disease. The vaccine is made of a weakened form of the virus that cannot cause disease but causes the body’s immune system to make antibodies that… …   English dictionary of cancer terms

  • hepatitis A vaccine inactivated — an inactivated whole virus vaccine derived from an attenuated strain of hepatitis A virus grown in cell culture; administered intramuscularly as an immunizing agent for preexposure prophylaxis in susceptible persons at least two years of age …   Medical dictionary

  • hepatitis B vaccine (recombinant) — an inactivated virus vaccine derived by recombination from hepatitis B surface antigen and cloned in yeast cells; administered intramuscularly for immunization of children and adolescents and of persons at increased risk for infection …   Medical dictionary

  • Hepatitis B — Classification and external resources Electron micrograph of hepatitis B virus ICD 10 B …   Wikipedia

  • hepatitis B surface antigen — n an antigen that is usu. a surface particle from the hepatitis B virus and that is found in the sera esp. of patients with hepatitis B abbr. HBsAg called also Australia antigen * * * (HBsAg) a coat protein antigen of the hepatitis B virus… …   Medical dictionary

  • Hepatitis A — Clasificación y recursos externos CIE 10 B15 CIE 9 070.1 …   Wikipedia Español

  • Vaccine — For other uses, see Vaccine (disambiguation). A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease causing microorganism, and is often made from… …   Wikipedia

  • Vaccine court — Cases before the Vaccine Court are heard in the U.S. Court of Federal Claims. Vaccine court is the popular term which refers to the Office of Special Masters of the U.S. Court of Federal Claims, which administers a no fault system for litigating… …   Wikipedia

  • Hepatitis C virus — Taxobox name = Hepatitis C virus image width = 160px image caption = Electron micrograph of Hepatitis C virus. The bar = 50 nm virus group = iv familia = Flaviviridae genus = Hepacivirus type species = Hepatitis C virus : This page is for the… …   Wikipedia

Share the article and excerpts

Direct link
… Do a right-click on the link above
and select “Copy Link”